Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853618 · ClinicalTrials.gov registry record · Phase 1
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT01853618: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01853618 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01853618, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
Background: \- Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer. The drug will be given with one of two types of treatment for liver cancer. The first type, transarterial catheter chemoembolization (TACE), injects chemotherapy drugs into the tumor through the main blood vessel that is feeding it. That blood vessel is then closed off to help keep the drugs in the tumor longer. The second type, radiofrequency ablation (RFA), uses a heated probe to destroy the tumor tissue. Researchers want to study how safe and effective these treatments are with the study drug. Objectives: \- To test the safety and effectiveness of Tremelimumab with TACE or RFA for advanced liver cancer. Eligibility: \- Individuals at least 18 years of age who have advanced liver cancer that has not responded to other treatments.
Interventions
- PROCEDURE Cryoablation
- DRUG Tremelimumab
- PROCEDURE TACE
- PROCEDURE RFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-05-02 |
| Est. Completion | 2017-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01853618
The ClinicalTrials.gov registry entry for NCT01853618 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cryoablation is the first listed.
NCT01853618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01853618 about?
NCT01853618 is a clinical study titled "Tremelimumab With Chemoembolization or Ablation for Liver Cancer". Background: \- Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer. The drug will be given with one of two types of treatment for liver cancer. The first type, transarterial...
What is the current status of trial NCT01853618?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2013-05-02. Estimated completion is 2017-06-07.
What interventions are being tested in trial NCT01853618?
The interventions under investigation include: Cryoablation (PROCEDURE), Tremelimumab (DRUG), TACE (PROCEDURE), RFA (PROCEDURE).
Who is sponsoring clinical trial NCT01853618?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.